Technology News and Research

RSS

DoD recommends funding for Synta's STA-9584 for prostate cancer study

Synta Pharmaceuticals Corp., a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today announced that the Department of Defense (DoD) has recommended STA-9584, a novel vascular disrupting agent (VDA) currently in pre-clinical development at Synta, be funded for study in advanced prostate cancer.

19 Nov 2010

Study compares effect on HT status in mid, late life on dementia risk

Compared to women never on hormone therapy, those taking hormone therapy only at midlife had a 26 percent decreased risk of dementia; while women taking HT only in late life had a 48 percent increased risk of dementia, according to Kaiser Permanente researchers.

19 Nov 2010

CNS-ASU book explores relationship between nanotechnology and equity

Scientists and policymakers both contend that investments in nanoscale science and engineering will create revolutions in areas as diverse as materials, drug delivery, cancer treatment, and space travel. The hope is that many of the problems of today can be addressed using nanotechnology enabled products.

19 Nov 2010

Study suggests pomegranate juice can ward-off complications in kidney disease patients

Studies in recent years have claimed multiple health benefits of pomegranate juice, including that it is a good source of antioxidants and lowers both cholesterol and blood pressure, especially in diabetic and hypertensive patients.

19 Nov 2010

Multinational team identifies novel retinal disease gene

A multinational team effort of Regensburg's Institute of Human Genetics, Washington University in St. Louis, other partners and Genomatix elucidated a transcriptional network in photoreceptors and thereby identified a novel retinal disease gene

19 Nov 2010

Zalicus presents data on novel synergistic drug combinations for cancer at EORTC-NCI-AACR Symposium

Zalicus Inc. presented data today on its discovery of novel synergistic drug combinations for the treatment of cancer at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics Meeting in Berlin, Germany on November 18, 2010.

19 Nov 2010

Alnylam presents data on RNAi technologies at MIT Center Summit

Alnylam Biotherapeutics, a division of Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, presented new data at the MIT Center for Biomedical Innovation's Biomanufacturing Summit from its platform efforts aimed at developing RNAi technologies for applications in biologics manufacturing.

19 Nov 2010

FDA approves new drug application for NEXTERONE Premixed Injection

Prism Pharmaceuticals, Inc. announced today that the U.S. Food & Drug Administration has approved the supplemental new drug application for NEXTERONE (amiodarone HCl) Premixed Injection, the first and only premixed intravenous (IV) bag formulation of the antiarrhythmic agent amiodarone IV.

19 Nov 2010

New findings show promising treatment for MS

Successfully treating and reversing the effects of multiple sclerosis, or MS, may one day be possible using a drug originally developed to treat chronic pain, according to Distinguished Professor Linda Watkins of the University of Colorado at Boulder.

19 Nov 2010

GWCI join forces with Banca Civica to fight cancer in Washington, D.C.

The GW Cancer Institute at The George Washington University Medical Center has joined forces with Banca Civica, a financial institution from Spain pioneering the innovative concept of civic banking, to fight cancer in Washington, D.C.

19 Nov 2010

Volpara breast imaging software receives FDA clearance

Offering radiologists a reliable and cost-effective tool to generate automatic volumetric breast density values, Volpara, Ltd., announced today that it has received clearance from the U.S. Food & Drug Administration for its Volpara breast imaging software. Volpara, a subsidiary of Matakina Technology, Limited of New Zealand, is responsible for commercial operations in the United States.

19 Nov 2010

Weight loss surgery ‘sky rockets’ in Australia

According to a new survey nearly ten times more people are resorting to weight loss surgeries in Australia over the past 10 years. In Australia one in five adults are now classified as being obese and this trend shows that public health messages about diet and exercise are not working.

18 Nov 2010

Nightingale second quarter revenue increases to $4.2 million

Nightingale Informatix Corporation, an application service provider (ASP) of electronic medical record (EMR) software and related services announces its financial results for the three- and six-month periods ended September 30, 2010.

18 Nov 2010

NTU to develop Five Peaks of Excellence under 5-year strategic plan

Nanyang Technological University (NTU) today unveiled NTU 2015, a five-year strategic plan that maps out how the university will become a great global university by 2015. Under this blueprint, NTU will build on its current strengths and heritage to make its mark globally in sustainability, healthcare, new media, the best of the East and West, and innovation.

18 Nov 2010

CDS implements eRAD's ASP hosted teleradiology software solution

eRAD, a division of RadNet, Inc., an industry leader in Web-based RIS, PACS and Teleradiology solutions, announced teleradiology service provider Century Digitec Services, Inc. (CDS) has gone live on eRAD's ASP Hosted Teleradiology Software Platform.

18 Nov 2010

Sirona fourth quarter revenue decreases 2.8% to $182.9 million

Sirona, the dental technology leader, today announced its financial results for the quarter and fiscal year ended September 30, 2010.

18 Nov 2010

CMOS processing compatible laser and 10Gb/s silicon modulator

CEA-Leti, coordinator of the European HELIOS project to accelerate commercialization of silicon photonics, said today project partners demonstrated a laser and a 10Gb/s silicon modulator using a process that is compatible with complementary metal-oxide semiconductor (CMOS) processing.

18 Nov 2010

Circassia announces positive result from phase II T-cell vaccine study for house dust mite allergy

Circassia Ltd, a specialty biopharmaceutical company focused on allergy, today announced successful clinical results from a phase II study of its T-cell vaccine targeting house dust mite allergy.

18 Nov 2010

Human Factors and Ergonomics Society releases new volume of annual series

The Human Factors and Ergonomics Society has just released the newest volume in the Reviews of Human Factors and Ergonomics annual series. Volume 6 reflects editor Douglas H. Harris's aim "to gain participation from the broadest range of expertise that exists in the Society and the profession.

18 Nov 2010

Anti-cancer drug smuggled using a nanocarrier past protective blood-brain barrier into brain tumours

Scientists in Germany have developed a way of smuggling an anti-cancer drug past the protective blood-brain barrier and into brain tumours and metastases using a nanocarrier - a tiny capsule specially designed to pass through cell membranes and deliver its anti-cancer drug to the cancer cell.

18 Nov 2010